Amalgamated Bank’s Faeth Therapeutics FTH Stock Holding History

Amalgamated Bank’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-126	Closed	-$6K	–	3184
2022 Q1	$6K	Buy	+126	New	+$10K	﹤0.01%	3019

Other funds holding FTH

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amalgamated Bank's FTH Position: Q2 2022 in Review

Amalgamated Bank sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 126 shares — an estimated $6K sold.

Amalgamated Bank first reported a position in FTH in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

Amalgamated Bank reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 126 Faeth Therapeutics shares in Q2 2022, an estimated $6K.
Amalgamated Bank first reported a position in Faeth Therapeutics in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Faeth Therapeutics position peaked at $6K in Q1 2022.
39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.